The "Anti-Obesity Drugs Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Molecule, Active Compound Used, Mechanism of Action, Type of Agonist, Action Pathway, Route of Administration, Geographical Regions, Sales Forecast and Key Players" report has been added to ResearchAndMarkets.com's offering.

The global anti-obesity drugs market is estimated to grow from USD 19.6 billion in 2025 to USD 104.9 billion by 2035, representing a CAGR of 18.3% during the forecast period.

The urgent need to address obesity epidemic globally has resulted in the boost of the anti-obesity drugs market. Factors such as increasing obesity prevalence, rising disposable incomes, and greater access to healthcare services are propelling this trend. The recent years have witnessed a rise in the approval of anti-obesity drugs, thereby expanding treatment options for patients. This is a result of the alarming statistics of approximately 40% of adults in the U.S. being classified as obese, with a body mass index (BMI) of 30 or higher.

The anti-obesity drugs target weight loss by regulating appetite, fat absorption, and metabolic processes. These drugs include various therapeutic options designed to assist individuals in managing obesity and related conditions. As global obesity rates increase and the awareness of associated health risks, including diabetes, cardiovascular diseases, and certain cancers rise, the need for effective anti-obesity medications has escalated. It is worth mentioning that, in the recent years, many new anti-obesity drugs have gained regulatory approval, expanding options for patients and offering alternatives to surgical procedures for weight loss.

Anti-obesity medications are vital in enhancing weight loss results, especially for patients with severe obesity-related health issues. Further, these drugs contribute to improved quality of life and can lower healthcare expenses by preventing complications related to obesity. Innovations in drug formulation and delivery systems, along with the integration of novel compounds, have resulted in the development of safer and more effective anti-obesity medications. The growing emphasis on personalized medicine and pharmacogenomics further enhances the potential for tailored treatments that address individual patient needs. Additionally, the rise in telehealth services and digital therapeutics applications is facilitating better patient engagement and adherence to treatment plans.

Public and private sectors are actively providing investments in order to conduct research and development in the anti-obesity space, along with fostering innovation and developing cutting-edge therapies. As the focus on obesity as a chronic disease that needs long-term management increases, the anti-obesity drugs market is poised for substantial growth, presenting significant opportunities for stakeholders in the coming years.

Anti-Obesity Drugs Market: Key Insights

The report delves into the current state of the anti-obesity drugs market and identifies potential growth opportunities within the industry.

Some key findings from the report include:

• Currently, close to 225 drugs are marketed / being developed for the management of obesity; around 50% of these can be administered through the oral route.
• Around 55% of the anti-obesity drugs are presently in their clinical stage of development; of these, majority of these drugs are being evaluated as monotherapy.
• A sizeable proportion (70%) of big pharma players have entered into various partnerships in order to expand their anti-obesity drug portfolios; majority of these partnerships (~30%) were research and development agreements.
• The growing awareness among patients about the health risks associated with obesity coupled with its increasing prevalence, is driving the anti-obesity market and positioning it for steady growth in the foreseeable future.
• The anti-obesity drugs market is anticipated to grow at an annualized rate (CAGR) of 18.3%, till 2035; North America is expected to capture the majority share (~60%) of the market by 2035.
• Currently, the centrally acting anti-obesity drugs dominate the market; notably, parenteral route of administration is expected to capture the majority share (~85%) in the market by 2035.

Anti-Obesity Market: Research Coverage

• Market Sizing and Opportunity Analysis: The report features a thorough analysis of the global anti-obesity drugs market, in terms of the key market segments, including type of molecule, active compound used, mechanism of action, type of agonist, action pathway, route of administration and geographical regions.
• Market Landscape: An in-depth assessment of the companies involved in anti-obesity market, based on several relevant parameters, such as including status of development, type of molecule, mechanism of action, type of agonist, route of administration, dosage frequency and type of therapy.
• Company Competitiveness Analysis: A comprehensive competitive analysis of ant-obesity drugs, examining factors, such as company strength and pipeline portfolio.
• Company Profiles: Detailed profiles of key service providers engaged in the anti-obesity drugs market, focused on overview of the company, financial information, pipeline portfolio, and recent developments and an informed future outlook.
• Big Pharma Initiatives A review of the various anti-obesity initiatives undertaken by big pharma players, highlighting trends across various parameters number of initiatives, year of initiative, type of initiative, type of partnership and type of expansion.

Key Players in the Antibody Contract Manufacturing Market Profiled in the Report Include

• Boehringer Ingelheim
• Eli Lilly
• Novo Nordisk
• Other Drug Developers
• Eli Lilly
• Pfizer
• Regeneron
• Kallyope
• CinFina Pharma
• Viking Therapeutics
• AstraZeneca
• Novo Nordisk
• Roche
• Adocia
• Boehringer Ingelheim
• Zealand Pharma
• Hanmi Pharm
• Jiangsu Hengrui Pharmaceuticals
• Gmax Biopharma
• PegBio
• QL Biopharm
• Sciwind Biosciences

Key Questions Answered in this Report

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

Additional Benefits

• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

Report Segmentation

Type of Molecule

• Biologics
• Small Molecules

Active Compound Used

• Tirzepatide
• Semaglutide
• Retatrutide
• Survodutide
• Cagrilintide and Semaglutide
• Orforglipron
• Liraglutide
• Other Active Compounds

Mechanism of Action

• GLP-1 Agonist / GIP Agonist
• GLP-1 Agonist / GCGR Agonist
• GLP-1 Agonist
• GLP-1 Agonist / Amylin Analogue
• GLP-1 / GCGR / GIP Agonist
• Other Mechanisms of Action

Type of Agonist

• Single-Agonist
• Dual-Agonist
• Tri-Agonist

Action Pathway

• Centrally Acting
• Peripherally Acting
• Centrally Acting and Peripherally Acting

Route of Administration

• Oral
• Parenteral

Geographical Regions

• North America
• Europe
• Asia
• Latin America
• Middle East and North Africa

Sales Forecast of Drugs

• Contrave / Mysimba
• Feisumei
• Imcivree
• LOMAIRA
• QSYMIA
• Saxenda
• Wegovy / Ozempic
• Zepbound / Mounjaro
• BI 456906
• CagriSema
• HM11260C
• HRS-9531
• IBI362
• LM-008
• LY3437943
• LY3502970
• TG103
• Semaglutide 7.2 mg (Subcutaneous)
• Semaglutide (Oral)
• XW003

For more information about this report visit https://www.researchandmarkets.com/r/bhr8g0

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251017334387/en/